After adjusting for standard clinicopathological variables, including age, post-treatment tumour size, and nodal status, the on-treatment LumA IS remained as an independent predictor of better TTR compared to LumB and HER2-E (Table 1). The gene discussed is ERBB2; the disease is neoplasm.